Omeros Corporation (Nasdaq: OMER) today announced that the first public presentation of its proprietary Targeted Complement Activating TherapyTM (T-CATTM) platform will occur at the European Congress ...
Dianthus Therapeutics, Inc. (DNTH) is advancing its potential best-in-class complement inhibitor drug DNTH103 for a wide variety of autoimmune disorders. In particular, it is looking at advancing the ...
An important part of the immune system is the so-called complement system. When the immune system detects a microorganism or other signs of danger, the complement protein C1 is converted into an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback